乌帕替尼治疗急性重度溃疡性结肠炎的多中心疗效经验
这项多中心研究纳入5家医院接受乌帕替尼联合静脉糖皮质激素治疗的25例急性重度溃疡性结肠炎患者,90天结肠切除率为24%(6例),18例有数据且未手术者中15例(83%)达到无激素临床缓解,1例(4%)发生静脉血栓栓塞事件,5例(20%)再入院;作者认为该联合方案可能有效。
要点
- 25例急性重度溃疡性结肠炎患者接受乌帕替尼联合静脉糖皮质激素治疗,90天结肠切除率为24%(6例)。
- 18例有数据且未行结肠切除的患者中,15例(83%)达到无激素临床缓解。
- 1例(4%)发生静脉血栓栓塞事件,5例(20%)再入院。
核心结论
- 乌帕替尼联合静脉糖皮质激素可能对急性重度溃疡性结肠炎有效。
研究设计与样本
- 多中心经验性研究,纳入5家医院接受乌帕替尼联合静脉糖皮质激素治疗的急性重度溃疡性结肠炎患者25例。
主要发现
- 25例患者中6例(24%)在90天内接受结肠切除。
- 18例有数据且未行结肠切除的患者中,15例(83%)达到无激素临床缓解,1例数据不完整。
- 1例(4%)发生静脉血栓栓塞事件,5例(20%)再入院。
临床怎么用
- 原文结论认为乌帕替尼联合静脉糖皮质激素可能对急性重度溃疡性结肠炎有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted. DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.
引用
- Berinstein JA, Karl T, Patel A, et al. Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience. Am J Gastroenterol. 2024. PMID: 38275248. doi:10.14309/ajg.0000000000002674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。